Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN44,4144,450,82
Msft2,28
Nokia3,233,2395-1,58
IBM0,73
Daimler AG44,1344,14-0,67
PFE0,81
26.09.2020 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.09.2020
Basilea Pharm (BSLN.S, Swiss Exchange)
Závěr k 25.9.2020 Změna (%) Změna (CHF) Objem obchodů (CHF)
47,32 1,50 0,70 2 332 216
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.09.2020
Popis společnosti
Obecné informace
Název společnostiBasilea Pharmaceutica AG
TickerBSLN
Kmenové akcie:Ordinary Shares
RICBSLN.S
ISINCH0011432447
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky30.06.2020
Počet zaměstnanců k 31.12.2019 225
Akcie v oběhu k 09.09.2020 10 802 604
MěnaCHF
Kontaktní informace
UliceGrenzacherstrasse 487
MěstoBASEL
PSČ4058
ZeměSwitzerland
Kontatní osobaPeer Schroeder
Funkce kontaktní osobyHead of Corporate Communications and Investor Relations
Telefon41 616 061 111
Fax41616061112
Kontatní telefon41 616 061 102

Business Summary: Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.
Financial Summary: BRIEF: For the six months ended 30 June 2020, Basilea Pharmaceutica AG revenues increased 17% to SF62.2M. Net income totaled SF9.9M vs. loss of SF15.4M. Revenues reflect Product revenue increase of 20% to SF30.5M, Contract Revenue increase of 14% to SF31.5M, Revenue Sales of Goods & Services increase of 66% to SF201K. Net Income reflects Research & development expenses, net decrease of 14% to SF43.9M (expense), Selling/General/Admin.
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research - NEC
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
NAICSDrug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICCommercial Physical Research
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 26.09.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board of DirectorsDomenico Scala5521.04.201609.04.2013
Chief Executive Officer, Member of the Management CommitteeDavid Veitch5519.04.201801.09.2014
Vice Chairman of the Board of DirectorsThomas Werner6401.01.2018
Member of the Management Committee, Chief Financial OfficerAdesh Kaul4610.04.201910.04.2019
Member of the Management Committee, Chief Technology OfficerGerrit Hauck5601.05.201801.05.2018
Member of the Management Committee, Chief Scientific OfficerLaurenz Kellenberger5327.01.200927.01.2009
General Counsel, Corporate SecretaryDamian Heller5401.01.2017
Head of Global Human ResourcesUrsula Eberhardt5801.01.2017
Member of the Management Committee, Chief Medical OfficerMarc Engelhardt5601.01.201801.01.2018
Head of Global Quality ManagementAnne Stehlin4401.01.2018